<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02232425</url>
  </required_header>
  <id_info>
    <org_study_id>IX-0103</org_study_id>
    <nct_id>NCT02232425</nct_id>
  </id_info>
  <brief_title>IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)</brief_title>
  <official_title>An 8-Week, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of IX-01 on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Lifelong Premature Ejaculation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ixchelsis Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HealthCore-NERI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PHT Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ixchelsis Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of IX-01 in men with lifelong
      premature ejaculation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Fold Change in Geometric Mean Intravaginal Ejaculatory Latency Time (IELT)</measure>
    <time_frame>Last 4 weeks of treatment compared to baseline</time_frame>
    <description>IX-01 versus placebo. Intravaginal ejaculatory latency time (IELT) was defined as the time from the initiation of sexual intercourse (penetration) until ejaculation occurred</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Rating Their PE as Better or Much Better, on the Clinical Global Impression of Change (CGIC) Scale</measure>
    <time_frame>Baseline to the end of treatment (approximately 8 weeks)</time_frame>
    <description>7 point scale ranging from much worse (-3) to much better (3). The proportion refers to the proportion of patients who had the best 2 possible responses [better(2) or much better (3)] on this 7 point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Greater Than or Equal to (≥) 2.5 Fold Increase in Intravaginal Ejaculatory Latency Time (IELT)</measure>
    <time_frame>Last 4 weeks of treatment compared to baseline</time_frame>
    <description>Intravaginal ejaculatory latency time (IELT) was defined as the time from the initiation of sexual intercourse (penetration) until ejaculation occurred. Outcome measured proportion of patients with at least a 2.5-fold increase in geometric mean IELT over the last 4 weeks of treatment as compared to baseline. Proportion of participants adjusted for baseline IELT, country and site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Arithmetic IELT (Intravaginal Ejaculatory Latency Time)</measure>
    <time_frame>Last 4 weeks of treatment compared to baseline</time_frame>
    <description>IX-01 versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Score on Control of Timing of Ejaculation</measure>
    <time_frame>Last 4 weeks of treatment compared to baseline</time_frame>
    <description>Reported in electronic diary and based on the Premature Ejaculation Profile (PEP). PEP question on control of timing is scored on a 5 point scale with the scores ranging from very poor (this is the worst answer) scored as 0 to very good (this is the best answer scored as 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Score on Ejaculation-related Personal Distress</measure>
    <time_frame>Last 4 weeks of treatment compared to baseline</time_frame>
    <description>Based on Premature Ejaculation Profile (PEP). Scale ranges from 'extremely' (0) to 'not at all' (4). An increase in score from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ≥ 1 Category of Improvement in Satisfaction With Sexual Intercourse, on the Premature Ejaculation Profile (PEP) Questionnaire</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Based on Premature Ejaculation Profile (PEP) 5 point scale with the scores ranging from 0 (worse answer) to 4 (best answer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ≥ 1 Category of Improvement in Control Over Ejaculation During Sexual Intercourse on the Premature Ejaculation Profile (PEP) Questionnaire</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Reported in electronic diary and based on the Premature Ejaculation Profile (PEP). PEP is scored on a 5 point scale with the scores ranging from 0 (worst answer) to 4 (best answer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ≥ 1 Category of Improvement in Ejaculation-related Distress on the Premature Ejaculation Profile ( PEP) Questionnaire</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Reported in e-diary. Based on Premature Ejaculation Profile (PEP). Scale ranges from 'extremely' (0) to 'not at all' (4). An increase in score from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ≥ 1 Category of Improvement in Ejaculation-related Interpersonal Difficulty on the Premature Ejaculation Profile (PEP) Questionnaire</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Reported in e-diary. Based on Premature Ejaculation Profile (PEP). Scale ranges from 'extremely' (0) to 'not at all' (4). An increase in score from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ≥ 2 Category Increase in Control and ≥ 1 Category Decrease in Personal Distress on a Patient Reported Outcome (PRO) Measure</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Reported in e-diary. Based on Premature Ejaculation Profile (PEP). Each of the PEP questions is scored on a 5 point scale with the scores ranging from 0 (worst answer) to 4 (best answer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Intercourse Attempts Lasting Longer Than 1 Minute From Baseline to Last 4 Weeks on Treatment</measure>
    <time_frame>Baseline to last 4 weeks on treatment</time_frame>
    <description>'Baseline' time period defined as Day -28 - Day 0. 'Last 4 Weeks' time period defined as the 28 days prior to last time subject took study drug and after Day 14.
Analysis excludes two subjects from ITT population: #010-012 (placebo) and #888-018 (active). Adjusted for treatment, baseline IELT, baseline percentage, country and site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-emergent Adverse Events</measure>
    <time_frame>Start of Treatment to end of study (approximately 10 weeks)</time_frame>
    <description>Number of participants with at least one treatment-emergent adverse event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Premature Ejaculation</condition>
  <arm_group>
    <arm_group_label>Drug: IX-01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IX-01</intervention_name>
    <arm_group_label>Drug: IX-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In stable (≥ 6 months) heterosexual relationship

          -  Have life-long (primary) premature ejaculation

          -  Have premature ejaculation confirmed by Intravaginal Ejaculatory Latency Time (IELT)
             less than or equal to (≤) 1 minute on ≥ 75% attempts at sexual intercourse

          -  Meet other aspects of the International Society for Sexual Medicine (ISSM) definition
             for lifelong premature ejaculation (PE), including inability to delay ejaculation on
             all or nearly all vaginal penetrations and negative personal consequences such as
             distress, bother and frustration

          -  Willing to attempt intercourse at least 4 times during run-in period and at least 8
             more times during double-blind part of the study

          -  Not planning pregnancy with his partner and he is willing to use contraception (unless
             not of child-bearing potential, e.g., surgically sterilised)

          -  Willing to limit use of alcohol on days in which they take study drug (not more than
             three drinks, where one drink is defined as a 12 ounce (oz), 360 milliliter (mL)
             bottle of beer, a 5 oz (150 mL) glass of wine, or a 1½ oz (45 mL distilled spirits)

          -  Capable of giving written informed consent

        Exclusion Criteria:

          -  An Intravaginal Ejaculatory Latency Time (IELT) value ≥ 2 minutes during run-in period

          -  Less than (&lt;) 4 attempts at sexual intercourse during run-in (screening may be
             extended or patient may be rescreened if there are extenuating circumstances)

          -  A rating of control of ejaculation as fair, good, or very good on the Premature
             Ejaculation Profile (PEP) questionnaire prior to study

          -  Co-existing Erectile Dysfunction - International Index of Erectile Dysfunction (IIEF)
             erectile function domain &lt; 22 during run-in

          -  Concomitant use of Phosphodiesterase 5 (PDE5) inhibitors, intracavernosal injections,
             penile implants, Selective Serotonin Reuptake Inhibitors (SSRI's) or
             Serotonin-Norepinephrine Reuptake Inhibitors (SSNRI's), tricyclic antidepressants (for
             example (e.g.) clomipramine), monoamine oxidase inhibitors, alpha blockers, 5 alpha
             reductase inhibitors (including propecia for hair loss), topical anaesthetics, and/or
             tramadol

          -  History (last 6 months) of use of Botox or similar product to treat premature
             ejaculation

          -  Unwilling to stop other treatments for premature ejaculation (including but not
             limited to pharmacological, herbal, multiple condoms, psychosexual treatment, prior
             masturbation)

          -  Other sexual disorder of patient or partner that could interfere with results

          -  Current active sexually transmitted disease

          -  Major medical condition of patient that could interfere with ability to have sexual
             activity and or require hospital treatment

          -  Body Mass Index (BMI) &gt; 40 kg/m2

          -  Participation in a clinical drug trial anytime during the 30 days prior to screening

          -  Human Immunodeficiency Virus (HIV) or hepatitis B

          -  History of clinically significant prostate disease

          -  History of myocardial infarction, coronary bypass surgery, coronary artery
             angioplasty, unstable angina, clinically evident congestive heart failure, cardiac
             pacemaker, or cerebrovascular accident

          -  Cardiac arrhythmia: significant cardiac arrhythmia shown on Electrocardiogram (ECG),
             or a known or suspected history of significant cardiac arrhythmias within last six
             months

          -  History of congenital QT prolongation and/ corrected QT (QTc) interval &gt; 450
             milliseconds (msec) using the Bazett formula

          -  Mean systolic cuff blood pressure (BP) &gt; 140 millimeter of mercury (mmHg), as assessed
             by up to three measurements taken in sequence within 5-10 minutes of last measure

          -  Mean diastolic cuff BP &gt; 90 mmHg, as assessed by up to three measurements taken in
             sequence within 5-10 minutes of the last measure

          -  Major psychiatric disease or risk of suicidal tendency as assessed by clinical
             evaluation and Patient Health Questionnaire (PHQ)-9 and Columbia Suicide Assessment

          -  PHQ-9 questionnaire total score &gt; 9 and/or score &gt; 0 for question 9 of PHQ-9, and/or
             suicidal ideation or behavior as assessed by Columbia Suicide Assessment

          -  Clinically significant abnormal laboratory function test results (including liver
             enzymes &gt; 2 x Upper Limit of Normal (ULN) or bilirubin &gt; 1.5 x ULN)

          -  Taking Cytochrome P450 3A4 (CYP3A4) inducers, or moderate and potent CYP3A4 inhibitors
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email Katie.George@Ixchelsis.com</last_name>
    <role>Study Director</role>
    <affiliation>Ixchelsis Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Diego Sexual Medicine</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research Inc.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Marital and Sexual Health of South Florida</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Research Institute</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants of Southeastern Pennsylvania</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miriam Hospital / The Men's Health Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Centre for Sexual Health</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keogh Institute for Medical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 3, 2014</study_first_submitted>
  <study_first_submitted_qc>September 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2014</study_first_posted>
  <results_first_submitted>November 1, 2018</results_first_submitted>
  <results_first_submitted_qc>January 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 24, 2019</results_first_posted>
  <disposition_first_submitted>September 21, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>September 22, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 23, 2016</disposition_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Premature Ejaculation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Drug: IX-01</title>
          <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug: IX-01</title>
          <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="9"/>
                    <measurement group_id="B2" value="43" spread="8"/>
                    <measurement group_id="B3" value="43" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Fold Change in Geometric Mean Intravaginal Ejaculatory Latency Time (IELT)</title>
        <description>IX-01 versus placebo. Intravaginal ejaculatory latency time (IELT) was defined as the time from the initiation of sexual intercourse (penetration) until ejaculation occurred</description>
        <time_frame>Last 4 weeks of treatment compared to baseline</time_frame>
        <population>Efficacy data set excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Fold Change in Geometric Mean Intravaginal Ejaculatory Latency Time (IELT)</title>
          <description>IX-01 versus placebo. Intravaginal ejaculatory latency time (IELT) was defined as the time from the initiation of sexual intercourse (penetration) until ejaculation occurred</description>
          <population>Efficacy data set excluding outliers</population>
          <units>Seconds</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.5" upper_limit="3.1"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.7" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Rating Their PE as Better or Much Better, on the Clinical Global Impression of Change (CGIC) Scale</title>
        <description>7 point scale ranging from much worse (-3) to much better (3). The proportion refers to the proportion of patients who had the best 2 possible responses [better(2) or much better (3)] on this 7 point scale</description>
        <time_frame>Baseline to the end of treatment (approximately 8 weeks)</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants Rating Their PE as Better or Much Better, on the Clinical Global Impression of Change (CGIC) Scale</title>
          <description>7 point scale ranging from much worse (-3) to much better (3). The proportion refers to the proportion of patients who had the best 2 possible responses [better(2) or much better (3)] on this 7 point scale</description>
          <population>Intent to treat, excluding outliers</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Better/Much Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44"/>
                    <measurement group_id="O2" value="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Greater Than or Equal to (≥) 2.5 Fold Increase in Intravaginal Ejaculatory Latency Time (IELT)</title>
        <description>Intravaginal ejaculatory latency time (IELT) was defined as the time from the initiation of sexual intercourse (penetration) until ejaculation occurred. Outcome measured proportion of patients with at least a 2.5-fold increase in geometric mean IELT over the last 4 weeks of treatment as compared to baseline. Proportion of participants adjusted for baseline IELT, country and site</description>
        <time_frame>Last 4 weeks of treatment compared to baseline</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Greater Than or Equal to (≥) 2.5 Fold Increase in Intravaginal Ejaculatory Latency Time (IELT)</title>
          <description>Intravaginal ejaculatory latency time (IELT) was defined as the time from the initiation of sexual intercourse (penetration) until ejaculation occurred. Outcome measured proportion of patients with at least a 2.5-fold increase in geometric mean IELT over the last 4 weeks of treatment as compared to baseline. Proportion of participants adjusted for baseline IELT, country and site</description>
          <population>Intent to treat, excluding outliers</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" lower_limit="0.14" upper_limit="0.54"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.01" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Arithmetic IELT (Intravaginal Ejaculatory Latency Time)</title>
        <description>IX-01 versus placebo</description>
        <time_frame>Last 4 weeks of treatment compared to baseline</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Arithmetic IELT (Intravaginal Ejaculatory Latency Time)</title>
          <description>IX-01 versus placebo</description>
          <population>Intent to treat, excluding outliers</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="2.2" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.9" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Score on Control of Timing of Ejaculation</title>
        <description>Reported in electronic diary and based on the Premature Ejaculation Profile (PEP). PEP question on control of timing is scored on a 5 point scale with the scores ranging from very poor (this is the worst answer) scored as 0 to very good (this is the best answer scored as 4)</description>
        <time_frame>Last 4 weeks of treatment compared to baseline</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Score on Control of Timing of Ejaculation</title>
          <description>Reported in electronic diary and based on the Premature Ejaculation Profile (PEP). PEP question on control of timing is scored on a 5 point scale with the scores ranging from very poor (this is the worst answer) scored as 0 to very good (this is the best answer scored as 4)</description>
          <population>Intent to treat, excluding outliers</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="-0.08" upper_limit="0.93"/>
                    <measurement group_id="O2" value="-0.03" lower_limit="-0.59" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Score on Ejaculation-related Personal Distress</title>
        <description>Based on Premature Ejaculation Profile (PEP). Scale ranges from 'extremely' (0) to 'not at all' (4). An increase in score from baseline indicates improvement.</description>
        <time_frame>Last 4 weeks of treatment compared to baseline</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Score on Ejaculation-related Personal Distress</title>
          <description>Based on Premature Ejaculation Profile (PEP). Scale ranges from 'extremely' (0) to 'not at all' (4). An increase in score from baseline indicates improvement.</description>
          <population>Intent to treat, excluding outliers</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" lower_limit="0.37" upper_limit="0.88"/>
                    <measurement group_id="O2" value="0.03" lower_limit="-0.34" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With ≥ 1 Category of Improvement in Satisfaction With Sexual Intercourse, on the Premature Ejaculation Profile (PEP) Questionnaire</title>
        <description>Based on Premature Ejaculation Profile (PEP) 5 point scale with the scores ranging from 0 (worse answer) to 4 (best answer).</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With ≥ 1 Category of Improvement in Satisfaction With Sexual Intercourse, on the Premature Ejaculation Profile (PEP) Questionnaire</title>
          <description>Based on Premature Ejaculation Profile (PEP) 5 point scale with the scores ranging from 0 (worse answer) to 4 (best answer).</description>
          <population>Intent to treat, excluding outliers</population>
          <units>adjusted proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.33" upper_limit="0.72"/>
                    <measurement group_id="O2" value="0.30" lower_limit="0.13" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With ≥ 1 Category of Improvement in Control Over Ejaculation During Sexual Intercourse on the Premature Ejaculation Profile (PEP) Questionnaire</title>
        <description>Reported in electronic diary and based on the Premature Ejaculation Profile (PEP). PEP is scored on a 5 point scale with the scores ranging from 0 (worst answer) to 4 (best answer)</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With ≥ 1 Category of Improvement in Control Over Ejaculation During Sexual Intercourse on the Premature Ejaculation Profile (PEP) Questionnaire</title>
          <description>Reported in electronic diary and based on the Premature Ejaculation Profile (PEP). PEP is scored on a 5 point scale with the scores ranging from 0 (worst answer) to 4 (best answer)</description>
          <population>Intent to treat, excluding outliers</population>
          <units>adjusted proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" lower_limit="0.42" upper_limit="0.69"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.19" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With ≥ 1 Category of Improvement in Ejaculation-related Distress on the Premature Ejaculation Profile ( PEP) Questionnaire</title>
        <description>Reported in e-diary. Based on Premature Ejaculation Profile (PEP). Scale ranges from 'extremely' (0) to 'not at all' (4). An increase in score from baseline indicates improvement.</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With ≥ 1 Category of Improvement in Ejaculation-related Distress on the Premature Ejaculation Profile ( PEP) Questionnaire</title>
          <description>Reported in e-diary. Based on Premature Ejaculation Profile (PEP). Scale ranges from 'extremely' (0) to 'not at all' (4). An increase in score from baseline indicates improvement.</description>
          <population>Intent to treat, excluding outliers</population>
          <units>adjusted proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" lower_limit="0.46" upper_limit="0.73"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.19" upper_limit="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With ≥ 1 Category of Improvement in Ejaculation-related Interpersonal Difficulty on the Premature Ejaculation Profile (PEP) Questionnaire</title>
        <description>Reported in e-diary. Based on Premature Ejaculation Profile (PEP). Scale ranges from 'extremely' (0) to 'not at all' (4). An increase in score from baseline indicates improvement.</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With ≥ 1 Category of Improvement in Ejaculation-related Interpersonal Difficulty on the Premature Ejaculation Profile (PEP) Questionnaire</title>
          <description>Reported in e-diary. Based on Premature Ejaculation Profile (PEP). Scale ranges from 'extremely' (0) to 'not at all' (4). An increase in score from baseline indicates improvement.</description>
          <population>Intent to treat, excluding outliers</population>
          <units>adjusted proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" lower_limit="0.45" upper_limit="0.72"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.29" upper_limit="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With ≥ 2 Category Increase in Control and ≥ 1 Category Decrease in Personal Distress on a Patient Reported Outcome (PRO) Measure</title>
        <description>Reported in e-diary. Based on Premature Ejaculation Profile (PEP). Each of the PEP questions is scored on a 5 point scale with the scores ranging from 0 (worst answer) to 4 (best answer)</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With ≥ 2 Category Increase in Control and ≥ 1 Category Decrease in Personal Distress on a Patient Reported Outcome (PRO) Measure</title>
          <description>Reported in e-diary. Based on Premature Ejaculation Profile (PEP). Each of the PEP questions is scored on a 5 point scale with the scores ranging from 0 (worst answer) to 4 (best answer)</description>
          <population>Intent to treat, excluding outliers</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Intercourse Attempts Lasting Longer Than 1 Minute From Baseline to Last 4 Weeks on Treatment</title>
        <description>'Baseline' time period defined as Day -28 - Day 0. 'Last 4 Weeks' time period defined as the 28 days prior to last time subject took study drug and after Day 14.
Analysis excludes two subjects from ITT population: #010-012 (placebo) and #888-018 (active). Adjusted for treatment, baseline IELT, baseline percentage, country and site.</description>
        <time_frame>Baseline to last 4 weeks on treatment</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Intercourse Attempts Lasting Longer Than 1 Minute From Baseline to Last 4 Weeks on Treatment</title>
          <description>'Baseline' time period defined as Day -28 - Day 0. 'Last 4 Weeks' time period defined as the 28 days prior to last time subject took study drug and after Day 14.
Analysis excludes two subjects from ITT population: #010-012 (placebo) and #888-018 (active). Adjusted for treatment, baseline IELT, baseline percentage, country and site.</description>
          <population>Intent to treat, excluding outliers</population>
          <units>percentage of attempts</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" lower_limit="17.8" upper_limit="57.3"/>
                    <measurement group_id="O2" value="13.5" lower_limit="-9.1" upper_limit="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Treatment-emergent Adverse Events</title>
        <description>Number of participants with at least one treatment-emergent adverse event</description>
        <time_frame>Start of Treatment to end of study (approximately 10 weeks)</time_frame>
        <population>Intent to treat, excluding outliers</population>
        <group_list>
          <group group_id="O1">
            <title>Drug: IX-01</title>
            <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-emergent Adverse Events</title>
          <description>Number of participants with at least one treatment-emergent adverse event</description>
          <population>Intent to treat, excluding outliers</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Two patients did not take any study medication hence 56 reported and not 58</desc>
      <group_list>
        <group group_id="E1">
          <title>Drug: IX-01</title>
          <description>Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
IX-01</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Two to four capsules administered orally, 1-6 hours prior to sexual activity
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Peridontal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lacerations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Metabolic function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis, allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor may choose to collaborate on authorship, and sponsor's agent has 60-day review</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Ixchelsis Limited</organization>
      <phone>44(0)1227-832760</phone>
      <email>ian.osterloh@ixchelsis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

